Effexor XR News
Wyeth discontinues Solvay partnership - Forbes
Wyeth is counting on Pristiq to replace its current antidepressant blockbuster Effexor XR, which accounted for $3.7 billion in sales last year but which ...
Business Highlights - Forbes
Effexor XR, Wyeth's extended-release depression drug, last year pulled in $3.8 billion - 17 percent of its total revenue. Cheaper generic competition is ...
Fitch Affirms Wyeth's 'A-' Ratings; Outlook Remains Stable - News & Observer
Moreover, Wyeth faces the loss of the US market exclusivity for its top-selling drug product, Effexor-XR, in July 2010. Sales of the drug have been ...
Pharma Blog Watch - FDA news (subscription)
The drug is, essentially, a version of Effexor XR, and Wyeth is hoping Pristiq can make its way to medicine cabinets because the Effexor patent expires in a ...
Wyeth Rises on Upgrade to 'Strong Buy' - CNNMoney.com
... are worth about $24.50 per share, and its other products, which include the antidepressant Effexor XR, are worth an additional $23.50 per share. ...
Fitch Affirms Wyeth's 'A-' Ratings; Outlook Remains Stable - FOXBusiness
Moreover, Wyeth faces the loss of the US market exclusivity for its top-selling drug product, Effexor-XR, in July 2010. Sales of the drug have been ...
Wyeth outlook cut to stable on launch of Protonix generic - Moody's - CNNMoney.com
... of a generic venlafaxine tablet product that, while not expected to be AB-rated, could negatively affect sales of Effexor XR, Wyeth's largest product. ...
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and ... - CNNMoney.com
Effexor(R) (Effexor and Effexor XR) continues to be the number one global antidepressant in sales and prescription volume and an important therapy in ...
Cellcom Israel Raises NIS 600 Million Through Private Offering Of ... - RTT News
Wyeth agreed to allow Teva to sell generic Effexor XR, the extended release version of the drug, in 2010, seven years ahead of its patent expiration. ...
Wyeth quarterly profit up 17%, yearly 10% - Philadelphia Inquirer
"The at-risk launch of Protonix generics and the loss of patent protection on Effexor XR in 2010 makes for lumpy earnings from 2008 to 2010," Tim Anderson, ...
Effexor XR RSS Feed